Pashtoon M. Kasi, MD, MS

Articles

Metastatic Colorectal Cancer: Future Directions in Care

April 3rd 2023

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

March 27th 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

Combination IO/TKI Strategies in Metastatic Colorectal Cancer

March 27th 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy

March 20th 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

Overview of Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer

March 20th 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer

March 13th 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial

March 13th 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial

March 6th 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

Importance of Identifying HER2 Status in Metastatic Colorectal Cancer

March 6th 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

Role of Tucatinib in HER2+ mCRC

February 27th 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Trastuzumab Deruxtecan in HER2+ mCRC

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

First-Line Treatment Options for mCRC

February 20th 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

Challenges With Molecular Testing in Metastatic Colorectal Cancer

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

December 18th 2020

Pashtoon M. Kasi, MD, MS, discusses findings from the CRC-MRD Consortia in colorectal cancer.

Dr. Kasi on the Role of MRD Testing in CRC

October 28th 2020

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Dr. Kasi on Utility of Personalized Medicine in Colorectal Cancer

January 21st 2020

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).